Aragen Life Sciences files IPO DRHP
Analysis based on 8 articles · First reported Aug 27, 2026 · Last updated Aug 27, 2026
The IPO filing signals a positive outlook for the Indian CRDMO sector, potentially attracting investor interest in pharmaceutical outsourcing. The fresh issue will strengthen Aragen's balance sheet and fund expansion, likely boosting its competitive position and market valuation.
Aragen Life Sciences, an Indian contract research, development and manufacturing organization (CRDMO), filed its draft red herring prospectus (DRHP) with the India — Securities and Exchange Board of India (SEBI) on August 27, 2026, for an initial public offering (IPO). The IPO comprises a fresh issue of ₹800 crore and an offer for sale (OFS) of up to 27,329,192 equity shares by existing shareholders, including promoters and investors such as Goldman Sachs Capital Holdings and entities of WSCPVIII. Proceeds from the fresh issue will be used to repay borrowings, fund capital expenditure at facilities in Hyderabad and at subsidiary Aragen Biologics Private Limited's Bengaluru facility, and for general corporate purposes. The company reported strong financial performance, with revenue from operations of ₹21,783.92 million and profit of ₹2,576.44 million in fiscal 2026, reflecting CAGRs of 14.64% and 26.86% respectively from fiscal 2024. Aragen serves 591 global customers and is among the top three Indian CRDMOs by operating revenue. The book-running lead managers are Axis Capital Holdings, Citigroup Global Markets India, Goldman Sachs (India) Securities, and JM Financial.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard